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Abstract
Seroprevalence studies have proven an important tool to monitor the progression of the coronavirus disease 2019 (COVID-
19) pandemic. We present results of consecutive population-based seroprevalence surveys performed in Denmark in 2020. 
In spring, late summer and autumn/winter of 2020, invitation letters including a questionnaire covering symptoms were sent 
to representative samples of the population above 12 years and to parents of children below 18 years in the sample. Blood 
samples were analysed for total Ig and seroprevalence estimates per population segment were calculated and compared to 
other surveillance parameters. Based on 34 081 participants (participation rate 33%), seroprevalence estimates increased 
from 1.2% (95%CI: 0.3–1.9%) in May to 4.1% (95%CI: 3.1–4.9%) in December 2020. Seroprevalence estimates were roughly 
three times higher in those aged 12–29 years compared to 65 + and higher in metropolitan municipalities. By December 2020, 
1.5% of the population had tested positive by RT-PCR. Infected individuals in older age groups were hospitalised several 
fold more often than in younger. Amongst seropositives, loss of taste/smell were the more specific symptoms, 32–56% did 
not report any symptoms. In more than half of seroconverted families, we did not see evidence of transmission between 
generations. Seroprevalence increased during 2020; adolescents were primarily infected in the autumn/winter. Denmark has 
a high per capita test rate; roughly one undiagnosed infection of SARS-CoV-2 were estimated to occur for each diagnosed 
case. Approximately half were asymptomatically infected. The epidemic appears to have progressed relatively modestly 
during 2020 in Denmark.
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Background
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) which causes COVID-19, manifests clinically rang-
ing from asymptomatic infection to severe disease, which 
may lead to death. Surveillance of laboratory confirmed 
SARS-CoV-2 infections will capture only infected persons 
who are tested; which may only be a fraction of all cases in 
the community. The degree to which the COVID-19 pan-
demic is spreading through different countries or regions 
may therefore instead be assessed through population-based 
seroprevalence studies, which aim to quantify the propor-
tion of the population that has developed antibodies against 
SARS-CoV-2. Such studies have been performed in a num-
ber of countries [1–9]. Some of these have been limited 
to specific geographic areas or been carried out on a non-
representative sample of the population, but those designed 
as national representative surveys have found substantial 
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geographical variability with higher seroprevalence in more 
densely populated areas [2, 7, 9, 10].
Similar to several other European countries, Denmark 
experienced increased transmission of SARS-CoV-2 infec-
tion in spring and late autumn 2020. A comprehensive lock-
down was imposed in March 2020, gradually lifted towards 
summer and again gradually reintroduced during autumn 
and winter [11]. The Danish National Seroprevalence Sur-
vey of SARS-CoV-2 infection (DSS) was initiated in the 
spring of 2020, following a parliamentary decision in April 
2020, which called for a representative population study to 
be performed. The study design was set by recommenda-
tion from two groups of independently appointed national 
experts in April 2020 [12, 13] and June 2020 [14] and the 
seroprevalence was subsequently determined at several time 
points throughout 2020. The aim of DSS was to follow the 
development of the COVID-19 epidemic by estimating the 
proportion of the population who had been infected with 
SARS-CoV-2, by age group, geography and sex at different 
time points, in order to guide preventive and control meas-
ures. Here we describe the set-up and results from the DSS 
in 2020 and relate the results to the national surveillance of 
RT-PCR diagnosed SARS-CoV-2-cases in Denmark.
Methods
Design and study population
DSS is a nationwide population-based prevalence survey 
aiming to investigate seroprevalence for SARS-CoV-2. 
The study should inform the national epidemic control in 
Denmark. It was launched in the spring of 2020 and per-
formed by Statens Serum Institut (SSI) over three rounds: In 
May 2020 (DSS-I), August 2020 (DSS-II) and September-
December 2020 (DSS-III).
In Denmark, a unique, personal civil registration number 
is assigned to all citizens, people with a residence permit, 
and people living outside Denmark but who are taxable in 
Denmark. For each survey round, a random population sam-
ple of Danish residents was drawn from the Danish civil 
registry [15] using the civil registration number. From the 
Danish civil registry, we also got information about age, 
sex and place of residence. For DSS-I, adults aged 18 years 
and older with an address in one of 30 municipalities which 
had a test facility (see below) at that time (n = 5), or were 
neighbouring a municipality with a test facility (n = 25) were 
eligible (approximately 45% of the population of Denmark). 
For DSS-II and DSS-III, people aged 12 years or older were 
selected by random sampling, with no restriction on munici-
pality (n = 98). To make it a safe experience for children and 
motivate participation, parents living on the same address 
as invited children 12–17 years old, were also invited to 
have an antibody test. Parents’ antibody test results were 
not included in the seroprevalence calculation.
Recruitment
Invitation letters (as pdf’s) were primarily sent via the 
secure, digital mailbox-system (“e-Boks”, the Danish digi-
talised postal system covering 90% of the Danish popula-
tion [16]), using the civil registration number. For invitees 
exempt from receiving public mails in e-Boks (primarily 
elderly citizens) and invitees below 18 years of age, a physi-
cal letter was sent by regular mail. For DSS-I we invited a 
total of 5200 people, 2600 on May 5 and 2600 on May 15. 
For DSS-II we invited 6000 people each week on August 15, 
21 and 28. For DSS-III we invited a total of 70 000 people 
over a 14 week period from September 11 to December 11, 
2020. Letters of invitation contained information about: the 
aim and study design, the antibody test (how to interpret and 
understand the test result), and how to book a test. DSS-II 
and DSS-III also included a link to an electronic question-
naire. Invitations and questionnaires were available in Dan-
ish, English and Arabic language versions. The question-
naire contained, amongst others, questions about current and 
past symptoms.
TestCenter Denmark, sample collection and analysis
Blood sampling was performed at test stations of ‘Test-
Center Denmark’, a public national SARS-CoV-2 test facil-
ity system established during March and April 2020 [17, 
18]. Nation-wide facilities offer free of charge, easy access 
RT-PCR testing for asymptomatic or mildly symptomatic 
individuals, in addition to the existing laboratories at the 
acute care hospitals that test symptomatic individuals and 
hospitalised patients upon admission. Booking of times-
lots for RT-PCR testing was accessible for the population 
through a secure website and easily done on a smartphone. 
By May 2020, 22 RT-PCR-test facilities had been estab-
lished, of which five facilities, one in each Danish region, 
were additionally equipped for taking blood samples. DSS-I 
made use of these five test stations. By August 2020, anti-
body testing could be carried out in 17 of the then 22 RT-
PCR-test facilities, distributed throughout the whole country 
and were used for DSS-II and DSS-III. Study participants 
could book timeslots for antibody testing using the same 
IT-platform as for RT-PCR testing. Transportation to a test 
facility was at participants’ own cost. Blood sampling was 
performed by medically trained personnel. Five ml of blood 
were taken in BD Vacutainer® Serum tubes. The blood sam-
ple was packed, collected and transported to SSI for analysis. 
Samples were stored at 5°C until analysis. Total serum con-
centration of anti-SARS-CoV-2 immunoglobulin (total Ig) 
was measured by use of the Wantai SARS-CoV-2 Ab ELISA 
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(Beijing Wantai Biological Pharmacy Enterprise, Beijing, 
China) according to the manufacturer’s instructions. The 
test had a sensitivity of 0.967 (CI95% 0.924–0.986) and a 
specificity of 0.995 (CI95% 0.987–0.998) [19].
Data source and the Danish COVID‑19 surveillance 
data
The Danish Microbiological Database (MiBa) contains 
all microbiological test results from all clinical microbio-
logical departments in Denmark and microbiological and 
serological results from TestCenter Denmark [20]. Tests are 
registered in MiBa in a person identifiable format, by use 
of the civil registration number. Using MiBa we identified 
antibody test results and previous SARS-CoV-2 RT-PCR-
test results amongst the study participants. From the Danish 
surveillance system of COVID-19 [21, 22] which is built on 
MiBa, we used information on the number of admitted and 
deceased RT-PCR-confirmed SARS-CoV-2 cases by date, 
sex and age group as well as the number of RT-PCR SARS-
CoV-2 tests carried out. The Danish surveillance system of 
COVID-19 involves daily registry linkage to the National 
Patient Registry [23] for information about hospital admis-
sions, and to the Civil Registry for information about sex 
and age, and The National Cause of Death Register [24] 
for information about deaths within 30 days for RT-PCR-
diagnosed COVID-19 cases.
Statistical analyses
We included all persons with a conclusive antibody test 
result within ten weeks from the invitation. We estimated 
the seroprevalence as the proportion of participating indi-
viduals with a positive antibody test result. We adjusted the 
seroprevalence estimates for test sensitivity and specificity 
using the Rogan-Gladen estimator [25] and computed 95% 
confidence intervals using Lang and Reiczigel’s method [26] 
which includes the accuracy of the sensitivity and specificity 
estimation. We present seroprevalence by age group, sex, 
the five geographical regions of Denmark and classification 
of municipality (capital, metropolitan, provincial, com-
muter, rural) as defined by Statistics Denmark [27] using 
information about the size of the biggest city and acces-
sibility of workplaces. To evaluate whether the variation in 
participation rate by age groups, sex and region affected the 
estimated seroprevalence, missing sero-prevalence results 
were imputed based on multiple imputation using a logis-
tic imputation model with sex, age group and region in the 
linear predictor in order to predict the missing 0 = nega-
tive/1 = positive response. The model was used to create 
100 imputed datasets, i.e. 100 predictions were done for 
each of the missing test results, and the resulting prevalence 
estimates were then derived by combining estimates from 
these 100 datasets using Rubin’s rules [28].
The period of data collection for DSS-III was longer than 
that of DSS-I and DSS-II, spanning 14 weeks of which that 
later period coincided with the start of a second surge of 
infections. Therefore, we used two time point for reporting 
of DSS-III, based on when the blood samples were taken. 
We thus defined four time points (May, August, October 
and December), based on the date of blood sampling for 
the estimation of the seroprevalence. In order to match the 
narrower geographic and age inclusion criteria for DSS-I, 
we also estimated the seroprevalence restricted to the same 
criteria. We compared the estimates of infected individu-
als based on the seroprevalence to the number of RT-PCR 
test positive, hospitalised and deceased SARS-CoV-2 cases 
captured in national surveillance. To do that, we subtracted 
14 days from the median date of blood sampling in each of 
the four periods to compare with RT-PCR-test positive from 
the national surveillance system. We added 10 days to find 
the comparable date for hospital admission and 20 days for 
number of deaths.
Ethical and legal considerations
The DSS was performed as a national disease surveillance 
project, registered with the Danish Data Protection Agency 
and approved regarding legal, ethical and cyber-security 
issues by the SSI Compliance department in conjunction 
with the Danish governmental law firm. Participation was 
voluntary and invitees received information about the selec-
tion procedure, risks associated with participation, data 
security issues, their legal rights, including the right to with-
draw from the study, and the use of their data and results in 
the letter of invitation.
Results
Participation
The three DSS study rounds had 2512 (48%), 7015 (39%), 
and 18 161 (26%) participants, respectively. Overall partici-
pation was lower in males and younger age groups (Table 1). 
For DSS-II and DSS-III respectively, the questionnaire was 
filled in by 2737 (39%) and 10 358 (57%) of the partici-
pants (Table 1). Eighty percent of those who participated did 
so within 12 days in DSS-I, within 31 days in DSS-II and 
within 20 days in DSS-III. The median dates of sampling 
for the four defined study periods were May 18 (referred to 
as ‘May’ below), September 19 (referred to as ‘August’), 
November 6 (‘October’), and December 16 (‘December’). 
Figure 1 shows the seroprevalence point estimates together 
with the invitation and data collection periods. For context, 
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the figure further illustrates the cumulative COVID-19 inci-
dence, weekly test intensity and level of national restrictions 
in Denmark in 2020. From Fig. 1 the smaller first wave and 
the bigger second wave can be seen and the rise in test inten-
sity during 2020, where it peaked in week 51 (December) 
with more than 15 tests per 100 population per week, is 
apparent.
Seroprevalence
The proportion of participants with detectable SARS-CoV-2 
antibodies increased from 1.2% (95%CI: 0.3%–1.9%) in 
May 2020 to 4.1% (95%CI: 3.1%–4.9%) in December 2020 
(Table 2). Restricting the analysis to match the narrower geo-
graphic and age inclusion criteria for DSS-I, the estimated 
seroprevalence in December was 6.7% (95%CI 5.1%–8.4%). 
When taking the non-participation by age group, sex and 
region of residence into account by imputation, the estimates 
increased with up to 0.3 percentage points (Table 2). Point 
estimates tended to be higher in the two younger age groups 
(12–17 years and 18–39 years of age), lower in the 65 years 
and older age group (Fig. 2), and higher in the Capital region 
than in the other four regions. No difference was observed 
by sex (Table 2).
Seroprevalence of children and their parents
A total of 1244 families had a child and at least one parent 
tested. Among these, 79 (6.4%) families were found to have 
at least one seropositive family member. These included 
3.2% with a seropositive child and 4.2% families with at least 
one seropositive parent. In 21 of the 79 seropositive fami-
lies (27%), both child and parent(s) were seropositive. In 
19 families (24%) only the child was seropositive, and in 
39 (49%) seropositive families the child was seronegative.
Symptoms amongst seropositive participants
Of the 369 seropositive participants who filled in the ques-
tionnaire, 59% reported having experienced at least one 
of four core symptoms (fever, cough, shortness of breath 
and/or loss of sense of taste or smell) since February 2020, 
Table 1  Number of invited persons and proportion who participated by DSS, age group, sex, and region
a Includes only people 18 years and older living in one of 30 municipalities which had a test facility at the time (n = 5) or was neighbouring a 
municipality with a test facility (n = 25). Approximately 45% of the population of Denmark
DSS Danish National Seroprevalence Survey of SARS-CoV-2 infection











% of participants who 
filled out question-
naire
Total 5200 (48) 18 000 (39) (38) 70 000 (26) (56)
Age group
12–17 years 1492 (31) (19) 5631 (20) (41)
18–39 years 2146 (40) 5715 (32) (31) 22 105 (22) (47)
40–64 years 2077 (56) 6700 (48) (42) 26 173 (33) (61)
65 + years 977 (50) 4093 (36) (46) 16 091 (22) (64)
Sex
Female 2585 (53) 9132 (44) (40) 35 282 (29) (59)
Male 2615 (44) 8868 (34) (36) 34 718 (23) (53)
Region
Capital 2167 (48) 5680 (42) (38) 22 268 (30) (55)
Zealand 619 (43) 2618 (39) (35) 10 107 (26) (54)
Southern Denmark 798 (46) 3737 (35) (39) 14 646 (20) (60)
Mid Jutland 1035 (52) 4108 (38) (42) 15 865 (23) (61)
North Jutland 581 (52) 1857 (40) (36) 7113 (29) (53)
Type of area (municipality)
Capital 2167 (48) 4985 (42) (38) 19 436 (30) (56)
Metropolitan 1526 (50) 2429 (43) (37) 9260 (28) (58)
Provincial 326 (44) 4070 (40) (39) 15 570 (26) (56)
Commuter 943 (48) 2848 (37) (42) 11 393 (24) (57)
Rural 238 (49) 3668 (33) (37) 14 341 (21) (56)
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versus 28% amongst seronegative participants (Table 3). 
Loss of smell or taste, reported by 28% of the seroposi-
tives, was highly associated with seropositivity (preva-
lence ratio of 9.8, Table 3).
In DSS-II 44% (95%CI: 32–56%) of the seropositive 
participants reported no symptoms since February and a 
further 9% reported symptoms not belonging to the five 
mentioned core symptoms. In DSS-III the equivalent fig-
ures were 27% and 11%.
Previous RT‑PCR positive participants
A total of 255 participants had had a positive RT-PCR-
test result prior to the antibody test. Of those, 232 had an 
antibody test 14 days or more after the positive RT-PCR 
result and SARS-CoV-2 antibodies were detected in 217 
(97% when adjusting for the sensitivity and specificity of 
the test) whereas 15 did not have detectable antibodies. 
The median time in days between the positive RT-PCR 
result and the positive antibody test result, amongst those 
with at least 14 days between the two, was 56 days [range: 
14–293] and 95 days [range: 17–188] for the 15 seronega-
tive persons.
Seroprevalence in relation to RT‑PCR‑diagnosed, 
admitted and deceased SARS‑CoV‑2 cases 
from national surveillance
According to the national COVID-19 surveillance system, 
78 125 persons above 12 years (1.53/100 inhabitants) had 
tested positive for SARS-CoV-2 by RT-PCR in Denmark 
by December 2 (Fig. 1). Our finding of a seroprevalence 
of 4.1% (95%CI 3.1–4.9) corresponds to a total of 208 000 
(157 000–249 000) persons above 12 years of age having 
been infected in Denmark by December 2, 2020. Thus the 
estimated ratio of infected persons to RT-PCR diagnosed 
persons captured in the national surveillance system was 
six in May 2020 and two in December (Table 4). The esti-
mated ratio varied by age. It was higher in the 18–39 year 
age group in May and August and decreased during 
autumn. No obvious pattern was seen for the 65-year and 
older age group or sex during the period (Table 4). The 
infection fatality rate and rate of admitted as a proportion 
of the estimated number of infected increased markedly 
with older age and was 3.8% in the 65-year and older age 
group (Table 4).
Fig. 1  Seroprevalence point estimates per survey period (%, grey 
dots), cumulative RT-PCR-confirmed SARS-CoV-2 cases (%, solid 
line), weekly number of SARS-CoV-2 RT-PCR tests (per 10 popula-
tion, dashed line), week of invitation for each survey (+ signs above 
the panel) and blood sampling (- signs above the panel) by ISO week, 
Denmark 2020. In addition, the timeline under the figure in schematic 
form illustrates the strength of the national measures that were in 
place to reduce transmission in 2020. In short, they comprised a full 
lockdown (shown using dark shading) involving a close-down of nor-
mal societal activity, but without imposing a curfew in March 2020 
(week 11). The lockdown was gradually lifted from late April (week 
16) into May. Over the summer, only comparatively mild restric-
tions were in place (regulating travel, gatherings, nightlife and more, 
shown using light shades). Starting September (week 34) restric-
tions were reintroduced and with an increasing incidence of infec-
tions occurring towards the end of the year. Harder restrictions were 
introduced in November (week 46) followed by a full lockdown being 
imposed in December (from week 50)
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Discussion
In this national representative seroprevalence study 
amongst Danish residents aged 12  years and older, 
we found detectable SARS-CoV-2 antibodies in 4.1% 
(95%CI: 3.1–4.9%) of the participants by the beginning 
of December 2020. This was four times more than the 
estimate from May and twice the estimate of August 2020. 
This study also provides information on the regional and 
demographic progression of the epidemic and the results 
can be interpreted in the context of other surveillance 
parameters.
Table 2  Seroprevalence of 
SARS-CoV-2 in four periods 
(May, August, October, and 
December) 2020, by age 
group, sex, region and type of 
municipality
a Includes only people 18 years and older living in one of 30 municipalities which had a test facility at the 
time (n = 5) or was neighbouring a municipality with a test facility (n = 25). Approximately 45% of the 
population of Denmark
b Adjusted for non-participation by sex, age group and region by multiple imputation






% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Total 1.2 (0.3–1.9) 2.1 (1.3–2.6) 2.2 (1.5–2.9) 4.1 (3.1–4.9)
Adjustedb total 1.5 (0.9–2.1) 2.0 (1.7–2.4) 2.4 (1.9–2.8) 4.3 (3.4–5.1)
Age group
12–17 years 1.0 (0–2.4) 2.9 (1.4–4.6) 6.5 (3.8–10)
18–39 years 2.3 (1.1–3.7) 2.9 (1.9–3.7) 3.3 (2.3–4.3) 5.3 (3.8–6.8)
40–64 years 0.6 (0.0–1.5) 2.0 (1.2–2.6) 2.0 (1.2–2.7) 3.6 (2.5–4.7)
65 + years 0.6 (0.0–2.1) 1.5 (0.6–2.3) 1.2 (0.3–2.0) 2.3 (1.0–4.0)
Sex
Female 0.9 (0.3–1.8) 2.1 (1.3–2.8) 2.0 (1.2–2.7) 4.2 (3.0–5.2)
Male 1.5 (0.5–2.6) 2.0 (1.1–2.6) 2.6 (1.7–3.3) 4.0 (2.8–5.2)
Region
Capital 1.8 (0.7–3.0) 3.2 (2.3–4.0) 3.3 (2.3–4.1) 5.0 (3.7–6.3)
Zealand 1.9 (0.2–4.6) 1.9 (0.9–2.8) 1.4 (0.4–2.3) 4.0 (2.3–6.1)
South 0.7 (0–2.5) 1.6 (0.6–2.4) 1.7 (0.7–2.6) 3.3 (1.8–5.0)
Mid Jutland 0.3 (0–1.6) 1.3 (0.4–2.0) 2.0 (1.0–2.9) 3.6 (2.1- 5.3)
North Jutland 0.6 (0–2.6) 1.2 (0.3–2.2) 1.6 (0.5–2.7) 3.1 (1.3–5.5)
Type of area (municipality)
Capital 1.8 (0.7–2.9) 3.3 (2.3–4.1) 3.5 (2.5–4.4) 5.6 (4.2–7.1)
Metropolitan 0.9 (0–2.1) 1.8 (0.8–2.7) 1.5 (0.5–2.5) 4.9 (3.1–7.1)
Provincial 3.2 (0.7–8.0) 1.5 (0.6–2.3) 2.3 (1.3–3.2) 3.6 (2.1–5.1)
Commuter 0 (0–1.3) 1.9 (0.9–2.8) 0.8 (0–1.6) 3.3 (1.8–5.3)
Rural 0 (0–1.2) 1.0 (0.1–1.8) 1.8 (0.8–2.7) 1.3 (0.2–2.9)
Fig. 2  Seroprevalence and 95% confidence intervals of SARS-CoV-2 in May, August, October, and December 2020, by four age groups, Den-
mark
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The seroprevalence varied by geography and age group, 
which is consistent with the general picture from the national 
surveillance system. It appears that people from more 
densely populated urban areas were infected in the early 
stage of the epidemic, and that the epidemic later gradually 
spread to the less densely populated areas. Our results are 
in line with the serological surveys of blood donors which 
have also been carried out in Denmark [29], although this 
group may not be representative of the general population.
Between May and December 2020, RT-PCR testing 
rose from 15 up to 150 tests per 1000 inhabitants per week. 
Our results show that the for each RT-PCR-confirmed 
SARS-CoV-2-case captured by the national surveillance 
system there were five undetected infections in the spring 
but just a little more than 1 by early December 2020. There 
were relatively more undiagnosed cases in the 18–39-year 
age group during the first six month of the epidemic, pos-
sibly because this age group experiences a less severe 
course of disease. It is well established that severity of ill-
ness increases markedly with age [30] and the estimated 
infection fatality and infection admission rates also increased 
markedly by age group in this study. Alternative use of a 
60-day mortality measure instead of a 30-day measure did 
Table 3  Number, proportion (%) of participants and prevalence ratio of symptoms, by antibody status, DSS-II and DSS-III, Denmark 2020
a In the period since 1 February 2020
b Core symptoms includes one or more of the following: fever, cough, shortness of breath and/or loss of sense of taste or smell
c Muscle ache, eye pain, head ache, coloured sputum, runny nose, sneezing, back pain, tiredness without one of the core symptoms
DSS: Danish National Seroprevalence Survey of SARS-CoV-2 infection
Symptoma Antibody test result
Positive (n = 369) Negative (n = 12 726) Prevalence ratio 95%CI
Number Proportion (%) Number Proportion (%)
No symptoms reported 112 (30) 7232 (57) 0.53 (0.46–0.62)
At least one core  symptomb 216 (59) 3508 (28) 2.1 (1.9–2.3)
Fever 139 (38) 1801 (14) 2.7 (2.3–3.1)
Cough 141 (38) 2544 (20) 1.9 (1.7–2.2)
Shortness of breath 71 (20) 811 (6) 2.8 (2.2–3.5)
Loss of sense of smell or taste 104 (28) 367 (3) 9.8 (8.1–12)
Other  symptomsc 41 (11) 1986 (16) 0.71 (0.53–0.95)
Table 4  Ratio between estimated number of infected and RT-PCR-
diagnosed SARS-CoV-2 cases from national surveillance at four time 
points and number of SARS-CoV-2 admissions, infection admission 
rate, number of SARS-CoV-2 deaths and infection fatality rate per 
December 2020, by age group and sex, Denmark 2020
a Includes only people 18 years and older living in one of 30 municipalities which had a test facility at the time (n = 5) or was neighbouring a 
municipality with a test facility (n = 25). Approximately 45% of the population of Denmark
b Among RT-PCR confirmed SARS-CoV-2 cases from national surveillance
IAR = Infection admission rate. IFR = Infection fatality rate
Estimated ratio of infected/PCR-diagnosed COVID-19 cases
Maya August October December Estimated number of 
infected by December 2
Admissions by 
December  12b
IAR (%) Deaths by 
December  22b
IFR (%)
Total 6 6 3 2 208 000 5987 2.9 1081 0.52
Age group
12–17 years – 5 4 3 26 000 58 0.22 0 –
18–39 years 13 7 4 2 84 000 642 0.76 3 0.00
40–64 years 3 5 3 2 69 000 2033 3.0 56 0.08
65 + years 3 6 3 3 27 000 3164 12 1022 3.8
Sex
Female 4 6 3 2 107 000 2790 2.6 480 0.45
Male 9 6 4 2 101 000 3107 3.1 601 0.60
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not change the infection fatality estimate markedly (0.52 vs. 
0.58).
National representative seroprevalence surveys from 
other countries have shown variable seroprevalence esti-
mates [31]: Surveys in France [10] in May, and Spain [2] 
and Brazil [9] in June and the Netherlands (7) in July 2020 
estimated that respectively around 4.5%, 5%, 3.5% and 4% of 
the population had been infected with SARS-CoV-2 at these 
timepoints. All four surveys revealed substantial geographi-
cal variability. In September 2020, a survey carried out in 
the US found that in 25 of 49 jurisdictions with sufficient 
samples to estimate seroprevalence, more than 5% of people 
had detectable SARS-CoV-2 antibodies [1]. Our results are 
comparatively low and thus the epidemic appears to have 
affected Denmark only mildly in 2020. This may be cor-
roborated by the cumulated mortality numbers, which by 31 
Dec 2020 were 23 per 100 000 [21], a low number relative 
to most other European countries [32].
Estimates from other studies [33, 34] of the proportion of 
asymptomatic infections out of the total number of SARS-
CoV-2 infections vary notably from a few percent to 41% 
with a pooled overall proportion of 17% found in a recent 
meta-analysis [35]. In DSS-II, carried out in the late sum-
mer, 44% of the seropositive participants, who filled out the 
questionnaire, did not recall having had any symptoms of 
acute infection since February 2020 and an additional 9% 
reported symptoms not typically associated with a SARS-
CoV-2 infection. The percentage reporting no symptoms 
since February 2020 fell to 27% in the DSS-III. However at 
this point other respiratory illnesses may increasingly have 
affected the results. Thus, our best estimate is that around 
41% of the seropositive persons experienced asymptomatic 
infections. The two younger age groups were less likely to 
have filled out the questionnaire. Because these groups are 
more likely to experience asymptomatic infections, the over-
all proportion of asymptomatic infections may be underes-
timated. We found that loss of smell or taste, experienced 
by 28% with SARS-CoV-2 antibodies, were by far the more 
specific symptoms of SARS-CoV-2 infection.
In more than two thirds of families with at least one 
seropositive family member, only the parent(s) or the child 
had seroconverted. Though household exposure is a strong 
risk factor for SARS-CoV-2 infection [36, 37], this find-
ing indicates that transmission between generations within 
households is the exception rather than the rule. This is in 
line with a previous meta-analysis which have estimated a 
secondary attack rate of 16.6% (95% CI, 14.0–19.3%) [38] 
and with two register-based studies carried out in Denmark 
where secondary attack rates between 10%-30% were found 
[11, 39]. However, a Norwegian study found an overall 
attack rate of 45% in households by use of serology [40]. 
We were unable to disentangle the direction of transmission 
between generations and our design did not allow us to shed 
light on seroconversion of siblings or other household mem-
bers who were not the legal parent of the child.
Though numbers were low, we found that < 5% of previ-
ous RT-PCR positive participants did not have detectable 
SARS-CoV-2-antibodies at least 14 days after their first 
positive RT-PCR test. This might be because of waning 
immunity, or that the individuals did not elicit a detectable 
antibody response (possibly due to mild or asymptomatic 
infection). The proportion does correspond to what has been 
reported from Iceland [41] and a study from the UK [6].
Denmark has a relatively high degree of IT penetration 
and frequently makes use of national registers and pub-
lic digital resources. Utilisation hereof was amongst the 
strengths of this study. From the Danish national civil reg-
ister, it was possible to obtain a random sample of residents, 
and identify the parents of those below 18 years of age. Indi-
vidually referable national surveillance data allowed us to 
identify all previous RT-PCR SARS-CoV-2 tests amongst 
the participants and relate this to their antibody-status. 
Another strength of the study was the use of the logisti-
cal set-up of the large state-driven nation-wide test-system, 
TestCenter Denmark, that was created as a parallel system 
to the existing clinical test system located at the hospitals. 
Using the existing set up for RT-PCR testing also for taking 
blood samples, meant that most people had an easy access 
to a test facility for antibody testing.
The study had several limitations. When interpreting 
the findings, the suboptimal participation and response 
rates should be taken into account. Participation decreased 
from 48% in DSS-I, through 39% in DSS-II to 26% in 
DSS-III, and even fewer replied to the questionnaire con-
cerning symptoms. It is possible that the low questionnaire 
response rate may be related to the lay-out of the invita-
tion letter, which generally highlighted the blood test. Also 
to be remembered is that even though the drawn sample 
is representative of the population, participation may not 
be. The seroprevalence estimates were stable but slightly 
underestimated when taking the non-participation by age 
group, sex and region of residence into account. However, 
we do not know if certain subgroups of the population 
were underrepresented in the study, but expect that factors 
such as distance to the nearest test facility, existing ill-
ness or immobility at the time of the invitation and ethnic 
background could have affected participation. In Denmark, 
some population groups with immigrant background are 
known to have been overrepresented among SARS-CoV-2 
cases [42]. If such groups had relatively lower participa-
tion rates in our study, there would be a tendency for an 
under-estimation of the true seroprevalence. Due to the 
geographical distribution of the test stations, some persons 
had quite long driving distances to a test facility (up to 
100 km for some), which may have affected their willing-
ness to participate in the study. If people living in remote 
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areas far from a test station had relatively lower participa-
tion rates, we may reversely have overestimated the true 
seroprevalence. Waning of antibodies may also have led us 
to underestimate the true seroprevalence. A waning effect 
would have been more likely to affect participants infected 
early in the pandemic and possibly primarily those with 
few or mild symptoms. In our study, we found antibodies 
in 95% of the participants that had previously tested posi-
tive by RT-PCR.
In conclusion, our study provides estimates of SARS-
CoV-2 dissemination in Denmark at four time points dur-
ing 2020, based on a representative sample of the popula-
tion and relate these to the number of RT-PCR-confirmed 
SARS-CoV-2 cases in the national surveillance system. 
We found that the epidemic had predominantly affected 
the capital and metropolitan areas and saw indications of 
a higher seroprevalence in young adults throughout the 
epidemic, although children 12–17 years old were mainly 
affected in the second surge of the epidemic. Overall, the 
estimated seroprevalence in Denmark throughout 2020 
was low, compared to other countries. The results seem to 
support that the measures introduced in Denmark in the 
spring of 2020 and onwards have been effective in keeping 
the epidemic from developing rapidly in the community, 
however also indicate that the majority of the population 
was still at risk of contracting SARS-CoV-2 infection at 
the end of 2020. As almost half of the infections seem 
to be asymptomatic, social distance measures and efforts 
to identify and isolate new cases and their contacts are 
imperative for future epidemic control in an unvaccinated 
population.
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